About Spansules Pharmatech Private Limited
Data last updated: 09 January 2026
Spansules Pharmatech Private Limited is a private limited company based in Hyderabad, Telangana, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 09 October 2000, the company has been in operation for over 26 years.
Registered with ROC Hyderabad under CIN U24230AP2000PTC035421.
Capital: an authorised share capital of ₹5 Cr and a paid-up capital of ₹5 Cr. It is led by directors including Rama Devi Guttikonda and Haswanth Rao Guttikonda.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Plot No.59 G – 3 Sri Venkateswara Towers Bhagyanagar Colony, Hyderabad, Telangana, India – 500072.
As per the financials filed for FY 2025, the company reported a revenue of ₹73.76 Cr, a decline of 4% compared to the previous year.
The company has a workforce of approximately 52 employees as per the latest available data.
The company is associated with 2 brands - Spansules Pharmatech, Spansules. As per MCA filings, the company has open charges of ₹57.24 Cr and satisfied charges of ₹8 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website spansulespharma.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media
-
Registered AddressPlot No.59 G – 3 Sri Venkateswara Towers Bhagyanagar Colony, Hyderabad, Telangana, India – 500072
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Spansules Pharmatech Private Limited
Spansules Pharmatech Private Limited has one previous CIN (Corporate Identification Number): U24230AP2000PTC035421. The current CIN is U24230TG2000PTC035421, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24230TG2000PTC035421 | Current |
| U24230AP2000PTC035421 | Previous |
Associated Brands with Spansules Pharmatech Private Limited
Spansules Pharmatech Private Limited operates two associated brands: Spansules Pharmatech and Spansules. These brands represent Spansules Pharmatech Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| A WHO GMP and ISO 9001:2008 certified manufacturer and exporter of pharmaceutical pellets. | spansulespharma.net | |
| Pharmaceutical pellet manufacturing and formulation development in India. | spansulespharma.com |
Competitors & Alternatives of Spansules Pharmatech Private Limited
Brands and companies operating in the same space as Spansules Pharmatech Private Limited include Concord Biotech, BDR Pharmaceuticals Internationals, Almac Group and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Concord Biotech
|
APIs and enzymes are manufactured through fermentation by the CDMO. | Ahmedabad, India, India | 2000 |
BDR Pharmaceuticals Internationals
|
APIs and finished products are developed and manufactured. | Mumbai, India, India | 2003 |
Almac Group
|
Integrated CDMO services for biopharma R&D and manufacturing are offered. | Craigavon, United Kingdom, United Kingdom | 2001 |
Indoco Remedies
|
APIs manufacturing and formulation services are provided in therapeutic segments. | Mumbai, India, India | 1947 |
Pharmaceutics International
|
Pharmaceutical dosage forms are manufactured by this CDMO. | Hunt Valley, United States, United States | 1994 |
Aurobindo Pharma
|
Generic biocatalytic solutions are provided for pharmaceutical applications. | Hyderabad, India, India | 1986 |
Seqens
|
Contract manufacturing services for small molecules and peptides are provided. | Ecully, France, France | 2003 |
Asymchem
|
APIs and peptides are developed and manufactured by Asymchem. | Morrisville, United States, United States | 1995 |
Aptuit
|
Contract research and development services for small molecules are offered. | Greenwich, United States, United States | 2004 |
Continuus Pharma
|
MIT-Novartis spinoff offering continuous manufacturing solutions to remove the proverbial wall between API and FDF manufacturing in small molecule development | Woburn, United States, United States | 2012 |
Business Activity of Spansules Pharmatech Private Limited
Spansules Pharmatech Private Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Board of Directors of Spansules Pharmatech Private Limited
Spansules Pharmatech Private Limited is governed by 4 directors who oversee the company's operations and strategic decisions.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rama Devi Guttikonda | Director | 09 Oct 2000 | 25 Years 9 Months | Current |
| Haswanth Rao Guttikonda | Director | 07 Feb 2020 | 6 Years 5 Months | Current |
| Harika Rao Guttikonda | Director | 07 Feb 2020 | 6 Years 5 Months | Current |
| Venkata Subba Rao Guttikonda | Managing Director | 09 Oct 2000 | 25 Years 9 Months | Current |
Financials of Spansules Pharmatech Private Limited FY 2025 filings available
Spansules Pharmatech Private Limited reported revenue of ₹73.76 Cr (down 4% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Charges & Borrowings of Spansules Pharmatech Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Sep 2025 | Canara Bank | ₹2 Cr | Open |
| 10 May 2022 | Hdfc Bank Limited | ₹20 Lakh | Open |
| 08 Feb 2022 | Hdfc Bank Limited | ₹24.77 Cr | Open |
| 27 May 2015 | Canara Bank | ₹8 Lakh | Open |
| 21 Oct 2010 | Canara Bank | ₹3 Lakh | Open |
Total charge records: 8 View all charges
Employees and EPFO Compliance at Spansules Pharmatech Private Limited
View historical data on people associated with Spansules Pharmatech Private Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Spansules Pharmatech Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Spansules Pharmatech Private Limited
GSTIN & GST Filing Data of Spansules Pharmatech Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Spansules Pharmatech Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Spansules Pharmatech Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Spansules Pharmatech Private Limited
MSME Payment Delays by Spansules Pharmatech Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Spansules Pharmatech Private Limited
Subsidiaries & Group Companies of Spansules Pharmatech Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Spansules Pharmatech Private Limited with ownership details.
MCA Filings & Documents of Spansules Pharmatech Private Limited
MCA Filings & Documents of Spansules Pharmatech Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Spansules Pharmatech Private Limited
Frequently Asked Questions about Spansules Pharmatech Private Limited
Spansules Pharmatech Private Limited is an active private limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 09 October 2000 (26+ years old) and is registered under CIN U24230TG2000PTC035421. The company has 52 employees.
Spansules Pharmatech Private Limited reported revenue of ₹73.76 Cr for FY 2025 (down 4.00% YoY).
The current directors of Spansules Pharmatech Private Limited are:
The primary industry of Spansules Pharmatech Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Spansules Pharmatech Private Limited can be reached at the registered office: Plot No.59 G – 3 Sri Venkateswara Towers Bhagyanagar Colony, Hyderabad, Telangana, India – 500072, or through the website spansulespharma.com.
The authorised capital is ₹5 Cr, and the paid-up capital is ₹5 Cr.